	Application No.	Applicant(s)
Notice of Allowability	10/664,601	BUCAY-COUTO ET AL.
	Examiner	Art Unit
	TIMOTHY E. BETTON	1627
	TIMOTHY E. BETTON	1027
The MAILING DATE of this communication appeal all claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in the or other appropriate communication. This application is sub-	nis application. If not included cation will be mailed in due course. THIS
1. \boxtimes This communication is responsive to <u>21 September 2010</u> .		
2. The allowed claim(s) is/are Claims 1-4, 6-14,16-21, and 33-38 allowable.		
 3. ☐ Acknowledgment is made of a claim for foreign priority une a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 		(f).
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	E Notice of Info	mal Detant Application
 Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) 	5. ☐ Notice of Infor 6. ☑ Interview Sum	mal Patent Application
	Paper No./Ma	ail Date <u>20100930</u> .
3. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>See Continuation Sheet</u>	7. ⊠ Examiner's Ar	nendment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ☐ Examiner's St	atement of Reasons for Allowance
	9. Other	
TEB		

Continuation of Attachment(s) 3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date: 1 page, 3/15/2004; 1 page, 6/13/2005; 2 pages, 12/27/2005.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with David B. Bonham on 30 September 2010.

The application has been amended as follows:

- 1. In claim 16 in the 1st line after form of claim <u>delete</u> 15 and <u>insert</u> 1
- 2. Delete withdrawn claims 22-32.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: The prior art of record does not fairly teach an injectable or insertable dosage form for producing specific necrosis of tissue that comes into contact with the dosage form comprising: a biodisintegrable binder and a chemical ablation agent in a concentration effective to cause necrosis of said tissue, wherein said dosage form is a sterile, solid or semi-solid dosage form, and said biodisintegrable binder comprises first and second biodisintegrable polymers, wherein at least one of said first and second biodisintegrable polymers is crosslinked at an outer surface of the dosage form.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

Application/Control Number: 10/664,601 Page 3

Art Unit: 1627

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for

Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to TIMOTHY E. BETTON whose telephone number is (571)272-

9922. The examiner can normally be reached on Monday-Friday 8:30a - 5:00p.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for

the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

TEB

/SREENI PADMANABHAN/

Supervisory Patent Examiner, Art Unit 1627